Scheduled Birth at Term for Pre-eclampsia Prevention: A Critical Analysis

Recent research suggests that scheduling birth at term for women identified as high-risk for pre-eclampsia may reduce the incidence of the condition without increasing rates of emergency caesarean section or adverse neonatal outcomes. The findings come from a carefully conducted trial reported by James Goadsby and colleagues, published in The Lancet on April 18, 2026. While the study indicates a potential benefit of planned delivery in specific high-risk pregnancies, experts caution that the results do not yet support widespread adoption of routine scheduled birth at term, particularly due to limitations in the study’s applicability to broader populations.

Pre-eclampsia, a pregnancy complication characterized by high blood pressure and signs of organ damage, remains a leading cause of maternal and fetal morbidity worldwide. Current clinical guidelines typically recommend expectant management for uncomplicated pregnancies, with delivery indicated only when maternal or fetal conditions deteriorate. However, for women identified as being at increased risk — such as those with chronic hypertension, prior pre-eclampsia, or certain biomarkers — the optimal timing of delivery has been less clear. The trial led by Goadsby aimed to evaluate whether a strategy of scheduled birth at 39 weeks’ gestation in this high-risk group could prevent the onset of pre-eclampsia compared to standard care.

The study enrolled women with singleton pregnancies deemed to be at elevated risk for pre-eclampsia based on established screening criteria. Participants were randomly assigned to either a planned delivery group, where labour was induced or caesarean section scheduled at 39 weeks, or a control group receiving standard antenatal care with delivery indicated only for medical reasons. The primary outcome was the incidence of pre-eclampsia, with secondary outcomes including rates of emergency caesarean section, neonatal intensive care unit admission, and other perinatal complications.

Results showed a statistically significant reduction in the development of pre-eclampsia among women in the scheduled birth group compared to those managed expectantly. Importantly, there was no significant difference between the groups in the rate of emergency caesarean section or in composite neonatal morbidity measures, suggesting that the intervention did not increase immediate risks to mothers or infants under the trial conditions.

Despite these findings, researchers and independent experts highlight several contextual factors that limit the generalizability of the results. The trial was conducted in a specialized obstetric setting with standardized protocols for induction and fetal monitoring, which may not reflect the variability seen in community hospitals or lower-resource environments. The study population, while high-risk, may not fully represent the spectrum of individuals currently managed expectantly in clinical practice, raising questions about whether the benefits would extend to a broader obstetric population.

Another consideration is the long-term implications of early-term delivery, even at 39 weeks, which is now considered term but may still carry subtle risks for neurodevelopment or respiratory adaptation compared to later-term birth. Although the trial did not detect significant short-term neonatal harm, the absence of long-term follow-up data means potential developmental effects cannot be ruled out. The psychological and logistical impact of scheduling birth — including increased maternal anxiety or reduced spontaneity in labour onset — was not formally assessed in the study.

Public health authorities and professional obstetric societies have not yet altered guidelines based on this single trial. Organizations such as the World Health Organization and the American College of Obstetricians and Gynecologists continue to emphasize individualized decision-making, weighing maternal risk factors against the benefits of allowing pregnancy to progress toward spontaneous labour when safe. The consensus remains that routine scheduled delivery should not be imposed without strong evidence of net benefit across diverse populations and healthcare settings.

Experts note that future research should focus on refining risk prediction tools to better identify those most likely to benefit from early delivery, while also evaluating outcomes in more varied clinical environments. Trials with longer follow-up, including childhood neurodevelopmental assessments, are needed to fully understand the trade-offs involved. Until such evidence accumulates, the approach of scheduled birth at term for pre-eclampsia prevention remains a promising but unproven strategy, best considered within the context of shared decision-making between patients and providers.